^
BIOMARKER:

PIK3CA mutation + PTEN mutation

i
Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K, PTEN, Phosphatase and
Entrez ID:
Related biomarkers:
Phase 2
Alliance for Clinical Trials in Oncology
Recruiting
Last update posted :
04/19/2022
Initiation :
08/01/2015
Primary completion :
10/01/2024
Completion :
10/01/2024
PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • SMO • CDK6 • CCND3 • CCND2
|
PIK3CA mutation • PTEN mutation • CDKN2A mutation • PTCH1 mutation • NF2 mutation • AKT1 mutation • PIK3CA mutation + PTEN mutation • SMO mutation • CDK4 mutation
|
Verzenio (abemaciclib) • capivasertib (AZD5363) • Erivedge (vismodegib) • GSK2256098
Phase 1
St. Joseph's Hospital and Medical Center, Phoenix
Active, not recruiting
Last update posted :
03/14/2022
Initiation :
12/21/2018
Primary completion :
06/30/2022
Completion :
07/31/2022
PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CDK4 • CDKN2B • PIK3R1 • PIK3C2B
|
PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation
|
everolimus • Kisqali (ribociclib)
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
02/25/2022
Initiation :
10/21/2019
Primary completion :
11/01/2022
Completion :
11/01/2022
HER-2 • ER • PIK3CA • PGR • PTEN • CCND1
|
HER-2 amplification • PIK3CA mutation • HER-2 negative • PGR positive • PIK3CA mutation + PTEN mutation
|
Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)
Phase 1
City of Hope Medical Center
Active, not recruiting
Last update posted :
02/21/2022
Initiation :
04/11/2018
Primary completion :
09/23/2022
Completion :
09/23/2022
BRAF • PIK3CA • PTEN
|
BRAF mutation • PIK3CA mutation • BRAF wild-type • RAS wild-type • PIK3CA mutation + PTEN mutation • RAS wild-type + BRAF wild-type
|
Mekinist (trametinib) • Lonsurf (trifluridine/tipiracil)
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
12/09/2020
Initiation :
10/01/2010
Primary completion :
07/01/2013
Completion :
07/01/2013
PIK3CA • PTEN
|
PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA mutation + PTEN mutation
|
dactolisib (RTB101)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
12/18/2018
Initiation :
03/01/2011
Primary completion :
08/01/2014
Completion :
08/01/2014
ER • PIK3CA • PTEN
|
ER positive • PIK3CA mutation • PIK3CA mutation + PTEN mutation
|
MK-2206
Phase 2
University of Utah
Withdrawn
Last update posted :
07/30/2014
Initiation :
05/01/2014
Primary completion :
07/01/2014
Completion :
07/01/2014
PIK3CA • PTEN
|
PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA mutation + PTEN mutation • PTEN-L
|
buparlisib (BKM120)